ALZAI and Linus Health Explore AI-Driven Collaborations Aimed at Early Identification of Alzheimer's Disease Risk and Cognitive Impairment
Ontario and Boston, Massachusetts--(Newsfile Corp. - August 11, 2026) - ALZAI Health Corp. (TSXV: ALZI) is pleased to announce that it has entered into a Memorandum of Understanding (MOU) with Linus Health, an AI-driven brain health company focused on early detection and proactive intervention. The companies intend to explore opportunities to use their complem
Technology, Computer Software, Healthcare and Hospitals
2026-08-11 6:00 AM EDT | Alzai Health Corp.
Medexus Announces Fiscal Q1 2027 Results With Strongest Quarter of Product-Level Performance of GRAFAPEX (Treosulfan) to Date
Fiscal Q1 2027 includes product-level net revenue from GRAFAPEX™ (treosulfan) for Injection of $4.9 million relative to $3.2 million of GRAFAPEX personnel and infrastructure investments Commercial traction observed to date reinforces Medexus confidence in the growth trajectory of GRAFAPEX Management to host conference call at 8:00 AM Eastern time on Tuesday, August 11, 2026
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-10 5:30 PM EDT | Medexus Pharmaceuticals Inc.
Theralase(R) Announces $5 Million Brokered LIFE Offering
Toronto, Ontario--(Newsfile Corp. - August 10, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses is pleased to announce that it has entered into an agreement with Research Capital Corporation ("RCC" or the "Age
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-08-10 5:15 PM EDT | Theralase Technologies Inc.
Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter of Fiscal Year 2027 Financial Results on August 14, 2026
Northvale, New Jersey--(Newsfile Corp. - August 10, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the first quarter financial results of the 2027 fiscal year will be released on Thursday, August 13, 2026. Elite's management will host a live conference call on Friday, August 14th, at 11:30 AM EDT to discuss the company's financial and o
Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-10 4:54 PM EDT | Elite Pharmaceuticals, Inc.
Envoy Medical Reports Second Quarter 2026 Results and Achieves Key Regulatory and Clinical Milestones
White Bear Lake, Minnesota--(Newsfile Corp. - August 10, 2026) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today re
Biotechnology, Healthcare and Hospitals
2026-08-10 8:00 AM EDT | Envoy Medical, Inc.
TelyRx Announces Second Quarter 2026 Financial Results
Clearwater, Florida--(Newsfile Corp. - August 10, 2026) - TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF) ("TelyRx" or the "Company"), a technology-enabled healthcare and digital pharmacy platform, today announced financial results for the second quarter ended June 30, 2026. All dollar amounts are expressed in U.S. dollars. Highlights for the Second Quarter of 2026 Revenue increased to $22.7 million, compare
Healthcare and Hospitals, Health
2026-08-10 7:00 AM EDT | TelyRx
Theralase(R) Grants Stock Options
Toronto, Ontario--(Newsfile Corp. - August 7, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, announces the grant of stock options. The Company has granted an aggregate of 7,000,000 stock options to eligible par
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-08-07 5:25 PM EDT | Theralase Technologies Inc.
Extendicare Announces 2026 Second Quarter Results
Markham, Ontario--(Newsfile Corp. - August 6, 2026) - Extendicare Inc. (TSX: EXE) ("Extendicare" or the "Company") today reported results for the three and six months ended June 30, 2026. Second Quarter 2026 Highlights Adjusted EBITDA(1) increased by $28.5 million or 71.7% from Q2 2025 to $68.3 million, driven primarily by contributions from the acquisitions of CBI Home Health and Closing the Gap, as well as continued
Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-06 5:00 PM EDT | Extendicare Inc.
Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update
King of Prussia, Pennsylvania--(Newsfile Corp. - August 6, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminat
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-06 4:05 PM EDT | Phio Pharmaceuticals Corp.
HEALWELL Achieves Revenue of $33 Million, Improved Operating Cash Flow and a Strengthened Balance Sheet in Q2-2026
HEALWELL achieved revenue from continuing operations of $33.0 million in Q2-2026 compared to revenue of $33.2 million in Q2-2025. Revenue remained consistent with the prior year, as one-time professional services revenue recognized in Q2 2025 did not recur in the current period. Excluding this impact, quarterly revenue reflects the Company's continued transition from episodic project-based engagements to higher-margin, recurring enterprise sales. HEALWELL
Technology, Healthcare and Hospitals
2026-08-06 4:05 PM EDT | HEALWELL AI
WELL Health Achieves Record Quarterly Revenue Milestone of $400 Million in Q2-2026, Driven by 32% Revenue Growth of Canadian Patient Services, and Raises 2026 Annual Guidance
WELL achieved quarterly revenues of $400.4 million in Q2-2026, an increase of 12% as compared to Q2-2025, driven by strong growth in the Company's Canadian Patient Services Business where quarterly revenue increased by 32% to $151.6 million in Q2-2026 as compared to Q2-2025. WELL achieved Adjusted EBITDA(1) of $48.1 million in Q2-2026, a decrease of 3% as compared to Q2-2025, representing an Adjusted EBITDA Margin(1) of 12%. The decrease reflects the impact
Technology, Computer Software, Healthcare and Hospitals, Health
2026-08-06 4:00 PM EDT | WELL Health Technologies Corp.
Kovo+ Announces Notice of Default and Demand Notice
Calgary, Alberta--(Newsfile Corp. - August 6, 2026) - Kovo+ Holdings Inc. (TSXV: KOVO) ("Kovo" or the "Company") announces that it, along with its wholly-owned subsidiaries including, without limitation, Kovo+ (USA) Inc. (formerly Medworxs, Inc.), Nexus AI Data Inc., Heal Global Holdings, Inc., AI Vector 2.0, Inc., Heal Vue, Inc., NOC5280 LLC, RPM Billing LLC, Kovo Acquisitions LLC, Kovo Human Capital LLC, and RSKM, LLC, have received a default notice and demand for repayment (t
Technology, Healthcare and Hospitals, Internet Technology
2026-08-06 1:02 PM EDT | Kovo+ Holdings Inc.
Jones Healthcare Group Expands Integrated Packaging Capabilities With Thermoforming Acquisition
London, Ontario--(Newsfile Corp. - August 6, 2026) - Jones Healthcare Group has acquired an operating thermoforming facility and related business assets in Brampton, Ont., adding in-house production of custom-formed packaging components to its integrated offering. The acquisition includes the facility, equipment and an experienced team of colleagues who will join Jones Healthcare. The addition complements the company's existing expertise in printed packaging components, contract packagi
Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-06 10:30 AM EDT | Jones Healthcare Group
NuGen Announces Non-Binding LOI to Acquire Sol-Millennium Canada
Toronto, Ontario--(Newsfile Corp. - August 6, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen" or the "Company") is pleased to announce it has entered a non-binding letter of intent ("LOI") with Sol-Millennium Medical HK Limited ("SolM HK"), the sole shareholder of Sol-Millenium Canada Inc. ("SolM"), dated August 5, 2026 to acquire all of the issued and outstanding common shares of SolM (the "Proposed Transaction"). Each party is curre
Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-06 8:07 AM EDT | NuGen Medical Devices Inc.
Adia Med to Host Dinner for Physicians at Christner's Steakhouse on August 5 to Discuss Clinical Studies and Collaboration Opportunities
Winter Park, Florida--(Newsfile Corp. - August 5, 2026) - Adia Med Inc. (OTCQB: ADIA), a regenerative medicine company focused on stem cell therapies and biologics, today announced that it will host a private dinner for physicians and investors on Wednesday, August 5, 2026, at 7:00 PM at Christner's Steakhouse.
Healthcare and Hospitals, Health
2026-08-05 4:30 PM EDT | Adia Med Inc.
HEALWELL AI Announces Conference Call for Second Quarter 2026 Financial Results on August 7, 2026
Toronto, Ontario--(Newsfile Corp. - August 4, 2026) - HEALWELL AI Inc. (TSX: AIDX) (OTCQX: HWAIF) ("HEALWELL" or the "Company"), a healthcare artificial intelligence company focused on preventative care, is pleased to announce the Company will release its Fiscal Second Quarter 2026 financial results for t
Technology, Healthcare and Hospitals
2026-08-04 4:00 PM EDT | HEALWELL AI
TelyRx Launches New Brand and Digital Experience Inspired by Patient Feedback
Clearwater, Florida--(Newsfile Corp. - August 4, 2026) - TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF), a technology-enabled healthcare and digital pharmacy platform, today announced the launch of its new brand platform and digital experience, designed around the needs of modern patients. Shaped by insights gathered from patients over the past two years, the launch represents a significant investment in building a healthcare bra
Healthcare and Hospitals, Health
2026-08-04 7:30 AM EDT | TelyRx
Elite Pharmaceuticals Announces Commercial Launch of Generic Requip XL
Northvale, New Jersey--(Newsfile Corp. - August 4, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, today announced that the company has launched Elite's generic version of Requip XL® (Ropinirole Extended-Release Tablets USP), with strengths of 2 mg, 4 mg, 6 mg, 8 mg, and 12 mg tablets. Ropinirole belongs to a class of drugs known as a non-ergoline dopamine agonist used to treat P
Healthcare and Hospitals, Pharmaceuticals, Health
2026-08-04 7:00 AM EDT | Elite Pharmaceuticals, Inc.
Theralase(R) Engages Global One Media to Expand Global Investor Awareness
Toronto, Ontario--(Newsfile Corp. - August 4, 2026) - Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical company dedicated to the research and development of energy-activated small molecules for the safe and effective destruction of cancer, bacteria and viruses, is pleased to announce that it has engaged Global One Media Group Pte. Ltd. ("Global One Media") to provide digital
Technology, Biotechnology, Healthcare and Hospitals, Pharmaceuticals
2026-08-04 7:00 AM EDT | Theralase Technologies Inc.
WELL Health Strengthens Executive Leadership Team with Appointments of Loreto Grimaldi as Chief Legal Officer and Kaytek Przybylski as Chief Digital & Information Officer
WELL appoints accomplished legal and business executive Loreto Grimaldi as Chief Legal Officer to lead legal, compliance, governance, risk management and M&A activities across the organization. Seasoned technology and digital transformation leader Kaytek Przybylski joins WELL as Chief Digital & Information Officer to lead enterprise technology, digital transformation, data, AI, and cybersecurity and technology shared services strategy.
Technology, Computer Software, Healthcare and Hospitals, Health
2026-08-04 6:30 AM EDT | WELL Health Technologies Corp.